Publications by authors named "Chrysanthi Koukoutzeli"
Antibody-drug conjugates (ADCs) have emerged as a transformative approach in cancer therapy by enhancing tumor targeting and minimizing systemic toxicity compared to traditional chemotherapy. Initially developed with chemotherapy agents as payloads, ADCs have now incorporated alternative payloads, such as immune-stimulating agents, natural toxins, and radionuclides, to improve therapeutic efficacy and specificity. A significant advancement in ADC technology is the integration of Proteolysis Targeting Chimeras (PROTACs), which enable the precise degradation of cellular targets involved in tumorigenesis.
View Article and Find Full Text PDFUse of Antibody-Drug Conjugates in the Early Setting of Breast Cancer.
Clin Med Insights Oncol
June 2024
Article Synopsis
- - Antibody-drug conjugates (ADCs) are specialized cancer treatments that combine monoclonal antibodies with toxic drugs to specifically target and kill cancer cells, showing effectiveness, particularly in breast cancer.
- - Ado-trastuzumab emtansine is currently the only approved ADC for early breast cancer, with several others available for metastatic cases, leading to new research exploring their use in early-stage treatment.
- - Ongoing clinical trials are focused on improving treatment strategies for early breast cancer and identifying which patients could benefit the most from these advanced therapies, emphasizing the potential for precision medicine.
Aims: Left ventricular ejection fraction (LVEF) calculation by echocardiography is pivotal in evaluating cancer patients' cardiac function. Artificial intelligence (AI) can facilitate the acquisition of optimal images and automated LVEF (autoEF) calculation. We sought to evaluate the feasibility and accuracy of LVEF calculation by oncology staff using an AI-enabled handheld ultrasound device (HUD).
View Article and Find Full Text PDFArticle Synopsis
- Antibody-drug conjugates (ADCs) are designed to deliver toxic agents specifically to cancer cells, and their integration with radiation therapy (RT) has the potential for both benefits and risks.
- ADC payloads can enhance the effects of radiation, but may also cause off-target toxicities due to their interaction with normal tissues that express the same antigens.
- There is a need for more clinical research to evaluate the safety and effectiveness of combining ADCs with RT, especially considering the unknown side effects and risks associated with such treatments.
Treatment optimization in early triple negative breast cancer.
Expert Rev Anticancer Ther
November 2023
Introduction: The treatment of early-stage triple-negative breast cancer (TNBC) has radically changed in recent years. Response to neoadjuvant treatment has provided prognostic information, and the achievement of a pathological complete response (pCR) is associated with improved prognosis. An exact treatment algorithm that embraces the trade-off of efficacy and toxicity in a risk-adapted manner has, however, not been consolidated.
View Article and Find Full Text PDFBackground: Limited data on immune checkpoint inhibitor (ICI)-induced pruritus per se and efficacy of different therapeutic modalities in its management exist.
Objective: To study the quantitative and qualitative characteristics of ICI-induced pruritus per se and to assess the efficacy of the therapeutic modalities usually applied.
Methods: We retrospectively reviewed the records of 91 patients who were under treatment with ICIs for any kind of neoplasia and developed pruritus during treatment.
Introduction: Nail toxicity represents one of the most common cutaneous adverse effects of both classic chemotherapeutic agents and new oncologic drugs, including targeted treatments and immunotherapy.
Objectives: We aimed to provide a comprehensive literature review of nail toxicities derived from conventional chemotherapeutic agents, targeted therapies (EGFR inhibitors, multikinase inhibitors, BRAF and MEK inhibitors) and immune checkpoint inhibitors (ICIs), including clinical presentation, implicated drugs and approaches for prevention and management.
Methods: Retrieved literature from PubMed registry database was reviewed to include all articles published up to May 2021 relevant to the clinical presentation, diagnosis, incidence, prevention, and treatment of oncologic treatment-induced nail toxicity.